The Biden administration has appealed a decision in which a federal court jury last year sided with Gilead Sciences over the rights to a pair of groundbreaking HIV pills — and at least $1 billion in royalties may be at stake.
At issue is a battle over patents for Truvada and a newer, upgraded version version called Descovy – two highly effective and lucrative medications – as well as the role played by the federal government in making it possible to prevent transmission of a highly infectious disease that plagued the American public for decades.
The U.S. Centers for Disease Control and Prevention, which had funded academic research into HIV prevention that later formed the basis for the pills, maintained that Gilead infringed its patent rights. The U.S. Department of Health and Human Services also contended that the company refused to reach a licensing agreement despite several attempts to strike a deal.
